DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients

  • DiaMedica Therapeutics Inc DMAC has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD). 
  • The trial is designed to evaluate the effect of DM199 across three cohorts, including African Americans (AA), non-diabetic and hypertensive (Cohort 1, n=12), IgA Nephropathy (IgAN) (Cohort 2, n=16), and diabetic kidney disease (DKD) (Cohort 3, n=28).
  • DM199 demonstrated clinically meaningful improvements in kidney function in Cohorts 1 and 2, as measured by simultaneously stabilizing estimated glomerular filtration rate (eGFR) and decreasing urine albumin-to-creatinine ratio (UACR). 
  • In hypertensive participants (Cohorts 1 and 3), DM199 also reduced blood pressure by clinically significant levels. 
  • In cohort 3, despite a significant decrease in blood pressure by -5/1 mmHg, the eGFR and UACR levels were stable.
  • DM199 was well tolerated across all cohorts, with no DM199 related severe adverse events (SAEs) or discontinuations due to drug-related adverse events (AEs). 
  • AEs were generally mild to moderate in severity, with the most common being local injection site irritation that resolved.
  • DM199 is a recombinant (synthetic) form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) that plays a vital role in regulating diverse physiological processes.
  • Price Action: DMAC shares are down 24.1% at $5.44 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsChronic Kidney Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!